Imaging agent developer ImaginAb has inked a collaboration and commercialization agreement with Danish pharmaceutical firm H. Lundbeck.
Under the terms of the deal, the two companies will collaborate on imaging of the central nervous system to investigate the use of re-engineered antibodies for accelerating the transport of biologic agents across the blood-brain barrier (BBB). Lundbeck and ImaginAb will collaborate to concurrently develop biologics with improved BBB transport, as well as imaging agents that are capable of quantifying kinetics and targeting efficacy, according to the firms.
The agreement also includes an option for Lundbeck to commercialize the results of the collaboration for both diagnostic and therapeutic uses.
